VENARUS PILLS 500MG
VENARUS PILLS 500MG - 30 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Orange-pink coated tablets, biconvex, oblong with rounded ends, with a risk; on cross section two layers are visible.
Diosmin 450 mg
hesperidin 50 mg
Excipients: gelatin, Magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc.
The composition of the shell: polyethylene glycol 6000, magnesium stearate, hydroxypropyl methylcellulose, sodium lauryl sulfate, titanium dioxide, ferric oxide red, ferric oxide yellow.
Venotonic drug. It has an angioprotective and venotonic effect.
It reduces the elasticity of the veins, increases their tone and reduces venous congestion. Reduces permeability, capillary fragility and increases their resistance. Improves microcirculation and lymphatic drainage.
With the systematic use reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of organic and functional nature.
T1 / 2 of the drug is 11 hours. Excreted in the urine and feces.
- venous insufficiency of the lower limbs of a functional and organic nature (feeling of heaviness in the legs, pain, convulsions, trophic disorders);
- acute and chronic hemorrhoids.
The drug should be taken orally.
With venous insufficiency 1-2 tab./day (at noon and in the evening during the meal).
For acute hemorrhoids, 6 pills per day for the first 4 days, then 4 pills per day for 3 days.
Others: dyspepsia, vegetative lability.
- lactation period;
- hypersensitivity to the drug.
PREGNANCY AND LACTATION
The use of the drug during pregnancy is possible, since the experiments did not show teratogenic effects, and to date there have been no reports of any adverse effects when using the drug in pregnant patients.
Use during lactation is contraindicated, since there are no data on the release of the drug in breast milk.
With exacerbation of hemorrhoids, the prescription of this drug does not replace the specific treatment of other anal disorders.
Treatment should not be long. If short therapy is ineffective, a proctologic study should be conducted and the therapy applied should be reviewed.
Data on drug overdose is not provided.
Data on drug interactions of the drug are not provided.
TERMS AND CONDITIONS
List B. The drug should be kept out of the reach of children, dry, protected from light, at a temperature not exceeding 25 ° C.